Venus Remedies Limited

BSE: 526953 NSE: VENUSREM
Venus Remedies Limited - pharma in Chandigarh, India. FY 2026 financials & compliance.
CIN L24232CH1989PLC009705 Incorporated 15 September 1989 ROC Chandigarh HQ Chandigarh, India
Active Listed - NSE: VENUSREM · BSE: 526953 Public Limited Company pharma
Market Cap
₹1,931 Cr
VENUSREM · NSE
Share Price
₹1,497.80
+3.68% today
Revenue
₹770 Cr
FY 2025-26 · +18.8% YoY
EBITDA
₹147 Cr
Margin 19.1%
Net Profit
₹103 Cr
FY 2025-26 · +173.7% YoY
P/E (TTM)
15.9x
P/B 2.7x
ROE
16.8%
ROCE 21.6%
Debt / Equity
0.01
Interest cover 0.0x

About Venus Remedies Limited

Data last updated:

Venus Remedies Limited is a public limited company based in Chandigarh, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 15 September 1989 and has been in existence for over 37 years.

The company is registered with the Registrar of Companies (ROC), Chandigarh, under CIN L24232CH1989PLC009705. The company has 1 GST registration on record, which is no longer active. It is a listed company as per MCA records. Its shares are listed on BSE: 526953 and NSE: VENUSREM.

The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹13.37 Cr. It was formerly known as Venus Glucose Private Limited. It is led by directors including Pawan Chaudhary (Managing Director) and Manu Chaudhary (Whole-Time Director).

Its last annual general meeting (AGM) was held on 22 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at SCO 857 2nd Floor C. No. 10 Nac Manimajra, Chandigarh, India – 160101.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹769.6 Cr, a growth of 18.8% compared to the previous year. For the same year it recorded a net profit of ₹102.79 Cr (net margin 13.4%) and EBITDA of ₹147.28 Cr (EBITDA margin 19.1%). The net worth stands at ₹663.75 Cr (up 18.3% YoY). Total assets are valued at ₹678.97 Cr (up 20.1% YoY).

The company has about 1,487 employees on its provident fund (EPFO) records.

The company is associated with 2 brands: Venus Medicine Research Center and Venus Remedies. As per MCA filings, the company has satisfied charges of ₹909.48 Cr on record. Court records list 99 cases involving the company, including 48 filed by the company and 51 filed against it; 13 cases are pending. The company has 162 deals on record (144 market trades, 13 secondary share transfers, 3 funding rounds), with disclosed funding of ₹77.62 Cr; the latest was in May 2025. Its 4 peer companies in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations) are compared by revenue, 1 larger and 3 smaller; the largest is Servier India Private Limited with revenue of ₹685.38 Cr. The company has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 11 overdue payments to 6 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website venusremedies.com.

Company details

CIN L24232CH1989PLC009705
Registration Number 009705
Incorporation Date 15 September 1989
ROC Chandigarh
Listing Status Listed - Listed on NSE (VENUSREM); Listed on BSE (526953)
Company Status Active
Compliance Status Active Compliant

CIN history

Venus Remedies has one previous CIN (Corporate Identification Number): L24232CH1989PTC009705. The current CIN is L24232CH1989PLC009705, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24232CH1989PLC009705Current
L24232CH1989PTC009705Previous
Key People
Pawan Chaudhary Managing Director Manu Chaudhary Whole-Time Director Peeyush Jain Whole-Time Director

Contact details

Venus Remedies Limited's registered office is in Chandigarh, Chandigarh. Its website is venusremedies.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    venusremedies.com
  • Social Media
  • Registered Address
    SCO 857 2nd Floor C. No. 10 Nac Manimajra, Chandigarh, India – 160101
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Venus Remedies Limited, buy the company report.

Comprehensive company report
Venus Remedies Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Venus Remedies operates two associated brands: Venus Medicine Research Center and Venus Remedies. Each brand links to its own profile.

BrandDescriptionWebsite
Venus Medicine Research Center
Delivers specialized bio-analytical services for drug development and research applications.vmrcindia.com
Venus Remedies
Research-based generic and antibiotic pharmaceuticals are manufactured.venusremedies.com

Business activity

The main business activity of Venus Remedies is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing21Manufacture of basic pharmaceutical products and pharmaceutical preparations

To see the full business activity and turnover split of Venus Remedies Limited, buy the company report.

Financials of Venus Remedies Limited

FY 2025-26 filings available

Venus Remedies Limited reported revenue of ₹769.6 Cr (up 18.8% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹770 Cr
+18.8% YoY
EBITDA
₹147 Cr
+131.9% YoY
Profit After Tax
₹103 Cr
+173.7% YoY
Net Worth
₹664 Cr
+18.3% YoY
Total Assets
₹679 Cr
+20.1% YoY
Total Debt
₹12.41 Cr
+634.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue770648601556600548339
Revenue growth+18.8%+7.7%+8.3%-7.4%+9.5%+61.5%-
EBITDA14763.5259.6060.0262.1244.610.66
EBITDA margin+19.1%+9.8%+9.9%+10.8%+10.4%+8.1%+0.2%
Profit before tax13471.8144.6537.9236.4248.55(8.03)
Net profit10337.5528.1426.5540.7438.32(3.14)
Net profit margin+13.4%+5.8%+4.7%+4.8%+6.8%+7.0%-0.9%
EPS (₹)76.8933.9021.3119.8730.4750.04(8.10)
Balance sheet
Total assets679566539511491459551
Net worth664561488460440400323
Total debt12.411.6941.3342.2942.8451.32220
Cash & bank29.6180.1068.0954.4550.4031.422.13
Net working capital161233264224189141218
Cash flow
Cash from operations15686.4437.2936.6341.1013277.60
Cash from investing(185)(76.86)(8.46)(58.10)(17.25)57.34(4.69)
Cash from financing(3.12)(1.02)(1.08)(0.57)(9.48)(162)(73.00)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue219179259180193137195177
Revenue growth (YoY)+13.5%+30.4%+33.1%+2.1%+13.3%+26.3%--
Other income0.512.624.952.521.713.416.7612.28
EBITDA42.5034.1963.4237.5230.9615.3829.0018.02
EBITDA margin+19.4%+19.1%+24.4%+20.8%+16.1%+11.2%+14.9%+10.2%
Depreciation9.546.776.756.566.176.184.715.41
Interest0.000.000.010.010.010.010.010.01
Profit before tax33.4730.0461.6133.4726.4912.6031.0424.88
Tax7.827.0714.117.896.363.0010.045.28
Net profit25.6522.9747.5025.5820.139.6021.0019.60
EPS (₹)19.1917.1825.5319.1415.067.1815.7114.66
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue769639575538577515322
Revenue growth+20.2%+11.2%+7.0%-6.8%+12.1%+59.6%-
EBITDA14469.9960.8861.5268.8137.692.91
EBITDA margin+18.7%+11.0%+10.6%+11.4%+11.9%+7.3%+0.9%
Profit before tax13179.0646.6540.3244.6641.05(6.26)
Net profit99.3144.4530.1328.9548.9830.82(2.17)
Net profit margin+12.9%+7.0%+5.2%+5.4%+8.5%+6.0%-0.7%
EPS (₹)74.2939.3222.8221.6736.6543.97(6.67)
Balance sheet
Total assets705592558526496455556
Net worth690590509478449400332
Total debt12.410.0038.6838.6838.6847.52216
Cash & bank28.0377.9967.6453.3049.9730.241.44
Net working capital175246269225182126212
Cash flow
Cash from operations15183.1035.3828.0541.0013277.15
Cash from investing(182)(76.20)(6.94)(50.81)(16.75)55.98(4.64)
Cash from financing(1.39)0.000.000.00(9.13)(162)(72.35)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue219179259180193137197172
Revenue growth (YoY)+13.6%+30.4%+31.7%+4.5%+13.5%+29.5%--
Other income0.402.554.642.411.682.724.0811.99
Total expenses173142200143163119171150
EBITDA45.6436.5659.4436.7229.8417.9325.2522.57
EBITDA margin+20.9%+20.4%+22.9%+20.4%+15.5%+13.1%+12.8%+13.1%
Depreciation9.276.516.516.325.925.954.495.20
Interest0.000.000.000.000.000.000.000.00
Profit before tax36.7732.6057.5732.8125.6014.7024.8429.36
Tax7.817.0714.127.896.363.0110.055.28

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 14 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue219179259180193137195177
Revenue growth (YoY)+13.5%+30.4%+33.1%+2.1%+13.3%+26.3%--
Other income0.512.624.952.521.713.416.7612.28
EBITDA42.5034.1963.4237.5230.9615.3829.0018.02
EBITDA margin+19.4%+19.1%+24.4%+20.8%+16.1%+11.2%+14.9%+10.2%
Depreciation9.546.776.756.566.176.184.715.41
Interest0.000.000.010.010.010.010.010.01
Profit before tax33.4730.0461.6133.4726.4912.6031.0424.88
Tax7.827.0714.117.896.363.0010.045.28
Net profit25.6522.9747.5025.5820.139.6021.0019.60
EPS (₹)19.1917.1825.5319.1415.067.1815.7114.66
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue770648601556600548339
Revenue growth+18.8%+7.7%+8.3%-7.4%+9.5%+61.5%-
Other income12.5830.8711.5810.328.3152.2436.66
Total expenses622584542495538504339
Employee cost0.0075.4666.9557.0552.3346.0246.02
EBITDA14763.5259.6060.0262.1244.610.66
EBITDA margin+19.1%+9.8%+9.9%+10.8%+10.4%+8.1%+0.2%
Depreciation25.6622.5126.4432.3033.5335.2832.01
Interest0.040.070.090.120.4813.0213.34
Profit before tax13471.8144.6537.9236.4248.55(8.03)
Tax31.3726.5116.1511.36(4.32)(13.21)1.96
Net profit10337.5528.1426.5540.7438.32(3.14)
Net profit margin+13.4%+5.8%+4.7%+4.8%+6.8%+7.0%-0.9%
EPS (₹)76.8933.9021.3119.8730.4750.04(8.10)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital13.3713.3713.3713.3713.3712.3412.34
Reserves & surplus650548474447427374311
Shareholders' funds (net worth)664561488460440400323
Minority interest0.000.000.000.000.000.000.00
Secured loans0.001.692.653.614.064.58173
Unsecured loans12.410.0038.6838.6838.7846.7447.87
Total debt12.411.6941.3342.2942.8451.32220
Total liabilities679566539511491459551
Assets
Gross block645637615604612616624
Net block232229219216241262289
Capital work in progress51.3626.3921.0826.1025.2325.1124.63
Investments23884.1019.1020.130.000.000.00
Inventories129100122120126120141
Sundry debtors10311280.5076.6638.6032.0430.69
Cash & bank balances29.6180.1068.0954.4550.4031.422.13
Loans & advances59.1574.8270.1551.6663.4050.59120
Total current assets321368340303278234294
Total current liabilities16013576.7778.9688.5792.9676.18
Net working capital161233264224189141218
Total assets679566539511491459551
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash57.5248.9621.2143.2628.881.942.03
Net cash from operating activities15686.4437.2936.6341.1013277.60
Net cash from investing activities(185)(76.86)(8.46)(58.10)(17.25)57.34(4.69)
Net cash from financing activities(3.12)(1.02)(1.08)(0.57)(9.48)(162)(73.00)
Net change in cash(32.41)8.5727.74(22.04)14.3826.94(0.09)
Closing cash29.6180.1068.0954.4550.4031.422.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+18.8%+7.7%+8.3%-7.4%+9.5%+61.5%-
EBITDA growth+131.9%+6.6%-0.7%-3.4%+39.3%+6659.1%-
PBT growth+86.8%+60.8%+17.8%+4.1%-25.0%+9998.0%+73.0%
Net income growth+173.7%+33.4%+6.0%-34.8%+6.3%+1320.4%-
Revenue CAGR (3Y)+11.5%+2.9%+3.1%+17.9%+23.1%+13.8%-5.3%
EBITDA CAGR (3Y)+34.9%+3.3%+10.1%+349.7%+38.1%+4.2%-76.5%
Profitability & leverage
Net income margin+13.4%+6.9%+4.7%+4.8%+6.8%+11.3%-2.9%
Return on capital employed+21.6%+10.9%+8.5%+7.6%+7.8%+7.6%+2.4%
Return on net worth+16.8%+5.7%+6.0%+5.9%+9.7%+10.6%-1.0%
Debt / equity0.010.040.090.090.110.380.79
Long-term debt / equity0.010.040.080.090.100.160.29
Interest cover0.030.150.270.431.68139.55-42.55
Efficiency & per share
Fixed asset turnover1.201.040.990.910.980.880.51
Inventory turnover6.705.884.984.524.894.202.39
Debtors turnover7.146.787.659.6416.9917.489.87
EPS (₹)76.9033.9021.3119.8730.4750.04(8.10)
Dividend per share (₹)10.000.000.000.000.000.000.00
Book value per share (₹)496.56419.65364.74344.38329.50313.18262.01
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue219179259180193137197172
Revenue growth (YoY)+13.6%+30.4%+31.7%+4.5%+13.5%+29.5%--
Other income0.402.554.642.411.682.724.0811.99
Total expenses173142200143163119171150
EBITDA45.6436.5659.4436.7229.8417.9325.2522.57
EBITDA margin+20.9%+20.4%+22.9%+20.4%+15.5%+13.1%+12.8%+13.1%
Depreciation9.276.516.516.325.925.954.495.20
Interest0.000.000.000.000.000.000.000.00
Profit before tax36.7732.6057.5732.8125.6014.7024.8429.36
Tax7.817.0714.127.896.363.0110.055.28
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue769639575538577515322
Revenue growth+20.2%+11.2%+7.0%-6.8%+12.1%+59.6%-
Other income11.4530.6911.3210.178.4350.3734.93
Total expenses625569514476508477319
Employee cost0.0067.2157.5747.6743.7535.8933.79
EBITDA14469.9960.8861.5268.8137.692.91
EBITDA margin+18.7%+11.0%+10.6%+11.4%+11.9%+7.3%+0.9%
Depreciation24.6921.6225.5531.3732.5834.2831.05
Interest0.000.000.000.000.0012.7313.05
Profit before tax13179.0646.6540.3244.6641.05(6.26)
Tax31.3726.5116.1511.36(4.32)(13.21)1.96
Net profit99.3144.4530.1328.9548.9830.82(2.17)
Net profit margin+12.9%+7.0%+5.2%+5.4%+8.5%+6.0%-0.7%
EPS (₹)74.2939.3222.8221.6736.6543.97(6.67)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital13.3713.3713.3713.3713.3712.3412.34
Reserves & surplus676576495465436374320
Shareholders' funds (net worth)690590509478449400332
Secured loans0.000.000.000.000.000.00168
Unsecured loans12.410.0038.6838.6838.6847.5248.34
Total debt12.410.0038.6838.6838.6847.52216
Total liabilities705592558526496455556
Assets
Gross block607601582568578582590
Net block215214203200225244271
Capital work in progress51.3626.3921.0826.1025.2325.1124.63
Investments23884.2419.2420.270.140.140.14
Inventories129100118114126120136
Sundry debtors11699.2689.5484.9230.4116.4429.78
Cash & bank balances28.0377.9967.6453.3049.9730.241.44
Loans & advances58.2173.9366.9246.2458.4047.37110
Total current assets332352342298264214278
Total current liabilities15710572.8172.6882.6187.8265.86
Net working capital175246269225182126212
Total assets705592558526496455556
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash55.4148.5120.0742.8327.701.261.28
Net cash from operating activities15183.1035.3828.0541.0013277.15
Net cash from investing activities(182)(76.20)(6.94)(50.81)(16.75)55.98(4.64)
Net cash from financing activities(1.39)0.000.000.00(9.13)(162)(72.35)
Net change in cash(31.86)6.9028.44(22.76)15.1226.450.16
Closing cash28.0377.9967.6453.3049.9730.241.44
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+20.2%+11.2%+7.0%-6.8%+12.1%+59.6%-
EBITDA growth+105.6%+15.0%-1.0%-10.6%+82.6%+1195.2%-
PBT growth+65.3%+69.5%+15.7%-9.7%+8.8%+9998.0%+77.8%
Net income growth+123.4%+47.5%+4.1%-40.9%+58.9%+1520.3%-
Revenue CAGR (3Y)+12.7%+3.8%+3.8%+18.6%+24.1%+13.2%-5.0%
EBITDA CAGR (3Y)+32.8%+2.9%+17.3%+176.5%+39.5%-4.7%-60.5%
Profitability & leverage
Net income margin+12.9%+8.2%+5.3%+5.4%+8.5%+10.5%-2.6%
Return on capital employed+20.2%+11.8%+8.6%+7.9%+9.4%+6.0%+2.6%
Return on net worth+15.5%+6.8%+6.2%+6.2%+11.5%+8.4%-0.7%
Debt / equity0.010.040.080.080.100.360.76
Long-term debt / equity0.010.040.080.080.100.160.28
Interest cover0.000.000.000.000.00373.31-46.38
Efficiency & per share
Fixed asset turnover1.271.091.000.940.990.880.51
Inventory turnover6.695.904.974.494.704.022.32
Debtors turnover7.136.836.599.3224.6222.2710.54
EPS (₹)74.2939.3222.8221.6736.6543.97(6.67)
Dividend per share (₹)10.000.000.000.000.000.000.00
Book value per share (₹)515.92441.01380.48357.63336.21313.10269.21

To see the full year-wise statements and ratios of Venus Remedies Limited, buy the company report.

Board of directors of Venus Remedies Limited

Venus Remedies has 10 current directors and 13 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Manu Chaudhary
Also directs: Sunev Pharma Solutions Limited
Whole-Time Director10 Oct 200521 Years 1 MonthsCurrent
Peeyush Jain
Also directs: Spine Software Systems Private Limited
Whole-Time Director28 Sep 199432 Years 1 MonthsCurrent
Ashutosh Jain
Also directs: Sunev Pharma Solutions Limited
Whole-Time Director01 May 200719 Years 6 MonthsCurrent
Pawan Chaudhary
Also directs: Sunev Pharma Solutions Limited, Spine Software Systems Private Limited
Managing Director15 Sep 198937 Years 1 MonthsCurrent
Navdeep SudDirector20 Jun 20206 Years 4 MonthsCurrent
Savita Gupta
Also directs: Itfy Info Solutions Private Limited
Director30 Dec 20214 Years 10 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Peer comparison

Venus Remedies Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Venus Remedies Limitedthis company₹769.6 Cr (FY 2026)₹102.79 Cr13.4%18.8%1,487Chandigarh, India
Servier India Private Limited₹685.38 Cr (FY 2025)35.0%Mumbai, Maharashtra, India
RPG Life Sciences Limited₹666.11 Cr (FY 2025)13.0%Mumbai, Maharashtra, India
Lincoln Pharmaceuticals Ltd₹645.71 Cr (FY 2025)5.0%Ahmedabad, Gujarat, India
Theon Pharmaceuticals Limited₹633.1 Cr (FY 2025)4.0%Chandigarh, India

To see the full peer comparison of Venus Remedies Limited, buy the company report.

Auditor

Venus Remedies Limited is audited by J.K. JAIN & ASSOCIATES for the financial year 2025.

Auditor firmFinancial yearFirm registration number
J.K. JAIN & ASSOCIATESFY 2025004025N

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 41.80%, foreign institutional investors hold 2.90%, domestic institutional investors hold 0.90% and retail and other public shareholders hold 54.40%.

Promoters: 41.80%DII (Domestic Institutional): 0.90%FII (Foreign Institutional): 2.90%Retail & Others: 54.40%
Sep 2026
QUARTER
41.80% Promoters
0.90% DII (Domestic Institutional)
2.90% FII (Foreign Institutional)
54.40% Retail & Others
Promoter holding - history
Now 41.80% · Sep 2026High 41.80% · Dec 2025Low 41.80% · Dec 2025
40%40.8%41.5%42.3%43%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 41.80%Mar 2026: 41.80%Jun 2026: 41.80%Sep 2026: 41.80%41.80%41.80%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters41.80%41.80%41.80%41.80%
Public58.20%58.20%58.20%58.20%

Charges & borrowings

Open charges
None
Satisfied charges
₹909.48 Cr
Breakdown by lending institutions
State Bank of India₹486.64 Cr
Idbi Bank Limited₹82.00 Cr
Dena Bank₹66.50 Cr
Ifci Limited₹50.00 Cr
Export-Import Bank of India₹50.00 Cr
Others₹174.34 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
10 Feb 201510558964Idbi Trusteeship Services Limited₹16.57 CrSatisfied
31 Mar 201410490888Dena Bank₹2 CrSatisfied
09 Jan 201410473597Andhra Bank₹5 CrSatisfied
09 Jan 201410473635Andhra Bank₹20 CrSatisfied
26 Nov 201310462278Dena Bank₹14.5 CrSatisfied

To see the full charge records of Venus Remedies Limited, buy the company report.

Total charge records: 42 View all charges

Deals & funding

Venus Remedies Limited has 162 deals on record (144 market trades, 13 secondary share transfers, 3 funding rounds), with disclosed funding of ₹77.62 Cr; the latest was in May 2025.

Total deals
162
Market trades
144
Secondary share transfers
13
Funding rounds
3
QIP
1
Disclosed funding
₹77.62 Cr

Deals on record (5 of 162)

WhenDealAmountParties
Feb 2025Market trade₹7.13 CrBuyer: Parth Infin Brokers Private Limited , Crony Vyapar Private Limited
Seller: Parth Infin Brokers Private Limited , Crony Vyapar Private Limited
Jun 2024Market trade₹2.6 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Nov 2023Market trade₹5.42 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Apr 2023Market trade₹1.49 CrBuyer: Yuga Stocks & Commodities Private Limited
Seller: Yuga Stocks & Commodities Private Limited
Oct 2021Market trade₹3.9 CrBuyer: XTX Markets LLP
Seller: XTX Markets LLP

To see the full deal history of Venus Remedies Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Venus Remedies Limited has 1 MSME Form 1 return on record for the period ending Mar 2019, listing 11 overdue payments to 6 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 6)

SupplierAmount dueDue sinceReported on
an individual supplier
MDC Pharmaceuticals Limited
Orison Pharma International
Ambica Pharma Machines Private Limited
Anantco Enterprises Private Limited

To see the full MSME payment records of Venus Remedies Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Venus Remedies Limited has a workforce of 1,487 employees on its EPFO records as of May 2026, across 2 active EPFO establishments.

Employee count
1,487
Active EPFO establishments
2
Employee growth
12.8%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-271,487
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17
FY 2015-16

To see the full employee and EPFO history of Venus Remedies Limited, buy the company report.

GST

Venus Remedies has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.

Total GSTINs
1
Cancelled / inactive
1

To see the full GST registrations and return filing status of Venus Remedies Limited, buy the company report.

Recent activity

Venus Remedies Limited has 34 board changes on record since 1989: 22 appointments and 12 cessations. The latest: Dr Gilbert Wenzel ceased to be Director on 30 Sep 2024.

Filing
Venus Remedies Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Chandigarh.
AGM
Venus Remedies Limited last Annual general meeting of members was held on 22 Aug 2025 as per latest MCA records.
Ceased
Dr Gilbert Wenzel ceased to be Director.
Ceased
Suresh Kumar Chadha ceased to be Director.
Appointed
Anil Kumar was appointed as Director.
Appointed
Jagdish Chander Sharma was appointed as Director.
Appointed
Nps Monga was appointed as Director.
Ceased
Pravindra Singh Chauhan ceased to be Director.
Appointed
Akshansh Chaudhary was appointed as Whole-Time Director.
Appointed
Savita Gupta was appointed as Director.
Charges
A charge registered on 10 Feb 2015 via Charge ID 10558964 with Idbi Trusteeship Services Limited was fully satisfied on 15 Mar 2021.
Charges
A charge registered on 29 Jun 2011 via Charge ID 10295788 with Idbi Trusteeship Services Limited was fully satisfied on 15 Mar 2021.

140 earlier events are in the company report.

News

VENUSREM: Q2 REVENUE 2.19B RUPEES VS 1.93B (YOY)
26 Oct 2026 · Exchange Update
VENUSREM: Q2 CONS NET PROFIT 257M RUPEES VS 201.3M (YOY)
26 Oct 2026 · Exchange Update
VENUSREM: Q2 EBITDA 425M RUPEES VS 309.6M (YOY); Q2 EBITDA MARGIN 19.43% VS 16.06% (YOY)
26 Oct 2026 · Exchange Update
Venus Remedies Ltd: Gains Five Marketing Approvals In Kazakhstan, Peru, Kuwait, And Argentina For Drugs Including Vancomycin, Fluorouracil, Fulvestrant, Methotrexate, And Meropenem; Enhances Global Reach And Pharmaceutical Offerings.
16 Oct 2026 · Exchange Update

Frequently asked questions

Venus Remedies is an active public limited company based in Chandigarh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 15 September 1989 (37+ years old) and is registered under CIN L24232CH1989PLC009705. Listed on BSE: 526953 and NSE: VENUSREM.

Venus Remedies reported revenue of ₹769.6 Cr for FY 2025-26 (up 18.8% YoY) based on consolidated financials.

Venus Remedies has 10 current directors:

The latest financial statements of Venus Remedies on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 22 August 2025. Year-wise statements from 2015 are in the company report.

No. Venus Remedies has 1 GST registration on record and it is cancelled or inactive.

The CIN (Corporate Identification Number) of Venus Remedies is L24232CH1989PLC009705. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Venus Remedies is a listed company as per MCA records. Its shares are listed on both BSE (code: 526953) and NSE (symbol: VENUSREM).

Venus Remedies has 99 court cases on record: 48 filed by the company and 51 filed against it. 13 are pending. Most are in the district courts.

Venus Remedies was incorporated on 15 September 1989, making it 37+ years old. It is registered with the Registrar of Companies, Chandigarh.

Venus Remedies has 162 deals on record (144 market trades, 13 secondary share transfers, 3 funding rounds), with disclosed funding of ₹77.62 Cr; the latest was in May 2025.

The peers of Venus Remedies by revenue are Servier India Private Limited, RPG Life Sciences Limited, Lincoln Pharmaceuticals Ltd, Theon Pharmaceuticals Limited, all in the Pharma industry (Formulations), with the same principal business activity (manufacture of basic pharmaceutical products and pharmaceutical preparations).

Dr Gilbert Wenzel ceased to be Director on 30 Sep 2024. Suresh Kumar Chadha ceased to be Director on 30 Sep 2024. Anil Kumar was appointed as Director on 13 Aug 2024. Venus Remedies has 34 board changes on record in total.